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Parkinson’s disease (PD) is characterized by the progressive
loss of the substantia nigra (SN) dopaminergic neurons project-
ing to the striatum. Neurotrophic factors may have the potential
to prevent or slow down the degenerative process occurring in
PD. To that end, we examined whether low amounts of glial cell
line-derived neurotrophic factor (GDNF) continuously released
from polymer-encapsulated genetically engineered cells are
able to prevent the loss of tyrosine hydroxylase immunoreac-
tivity (TH-IR) in SN neurons and ameliorate the amphetamine-
induced rotational asymmetry in rats that have been subjected
to a unilateral medial forebrain bundle (MFB) axotomy. Baby
hamster kidney (BHK) cells transfected with the cDNA for
GDNF were encapsulated in a polymer fiber and implanted
unilaterally at a location lateral to the MFB and rostral to the SN.
ELISA assays before implantation show that the capsules re-
lease ;5 ng of GDNF/capsule per day. One week later, the
MFB was axotomized unilaterally ipsilateral to the capsule
placement. Seven days later, the animals were tested for
amphetamine-induced rotational asymmetry and killed. The
striatum was excised and analyzed either for catecholamine
content or TH-IR, while the SN was immunostained for the
presence of TH-IR. GDNF did not prevent the loss of dopamine
in the striatum. However, GDNF significantly rescued TH-IR
neurons in the SN pars compacta. Furthermore, GDNF also
significantly reduced the number of turns per minute ipsilateral
to the lesion under the influence of amphetamine. Improvement
of rotational behavior in the absence of dopaminergic striatal
reinnervation may reflect neuronal plasticity in the SN, as sug-
gested by the dendritic sprouting observed in animals receiving
GDNF. These results illustrate that the continuous release of
low levels of GDNF close to the SN is capable of protecting the
nigral dopaminergic neurons from an axotomy-induced lesion
and significantly improving pharmacological rotational behavior
by a mechanism other than dopaminergic striatal reinnervation.
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Parkinson’s disease (PD) is a neurodegenerative disorder charac-
terized by the progressive loss of dopaminergic neurons in the
substantia nigra (SN) pars compacta, resulting in resting tremor,
rigidity, bradykinesia, and postural imbalance (Goetz et al., 1989).
Symptomatic therapy with the dopamine precursor levodopa,
although effective in the first few years of administration, leads
over time to deleterious side effects such as hallucinations and
sudden freezing episodes (Goetz et al., 1989). A neuroprotective
treatment that would slow down, prevent, or even reverse the
degeneration process is, therefore, needed. Neurotrophic factors
are known to play important roles in the development of neural
tissue. They also play a vital role in the protection of neurons
against various insults. Several neurotrophic factors, such as
brain-derived neurotrophic factor (BDNF), have shown promise
in the rescue of dopaminergic neurons in vitro. However, their
effectiveness in vivo has been, for the most part, somewhat less
promising (Knu¨sel et al., 1992; Hagg and Varon, 1993; Lapchak et
al., 1993). Glial cell line-derived neurotrophic factor (GDNF) was
reported specifically to enhance the survival of midbrain dopami-
nergic neurons in vitro (Lin et al., 1993). GDNF also has been
reported to exert protective effects on degenerating dopaminergic
neurons in vivo. Injections of GDNF into the striatum of C57/Bl6
mice before 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) treatment prevent the decrease in dopamine levels
(Tomac et al., 1995). A single intranigral injection of GDNF 24 hr
before a 6-OHDA nigral lesion rescues tyrosine hydroxylase im-
munoreactivity (TH-IR) for at least 2 weeks in rats (Kearns and
Gash, 1995). Sauer et al. (1995) have reported that repeated
intranigral injections of GDNF after a striatal 6-OHDA lesion
also prevent the loss of nigral TH-IR in rats. A bolus injection of
GDNF 4 weeks after a nigral 6-OHDA lesion in rats also main-
tains nigral dopamine levels (Hoffer et al., 1994) and TH-IR
(Bowenkamp et al., 1995) for 5 weeks. More recently, Gash et al.
(1996) have reported a bilateral improvement of the parkinsonian
symptoms in primates unilaterally lesioned with the neurotoxin
MPTP that have received three monthly bolus 100 mg doses of
GDNF into their lateral ventricles. A major concern with all of
these reports, however, is the large amounts (tens to hundreds of
micrograms) of GDNF being injected into the brain, because the
actions of GDNF are limited not only to dopaminergic neurons.
GDNF has been shown to increase choline acetyltransferase ac-
tivity (ChAT) in cranial motor nuclei and spinal motoneurons in
vitro and to prevent the death of motoneurons in vivo (Henderson
et al., 1994; Zurn et al., 1994; Li et al., 1995; Yan et al., 1995;
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Sagot et al., 1996). GDNF mRNA is expressed widely within the
adult (N. A.-M. Pochon and P. Aebischer, unpublished observa-
tions) and embryonic rat brain (Schaar et al., 1993; Stro¨mberg et
al., 1993; Humpel et al., 1994; Springer et al., 1994). For these
reasons, the ability to rescue neurons without the injection of
massive amounts of factor would be advantageous for the clinical
application of this factor.
One method of achieving continuous release of small amounts
of GDNF relies on the transplantation of cells that have been
engineered to release GDNF. Cell lines offer the advantages of
unlimited availability, suitability for stable gene transfer via non-
viral vectors, screening possibility for adventitious agents before
transplantation, and establishment of certified cell banks. The risk
of tumor formation can be controlled by the encapsulation tech-
nology with xenogeneic cell lines. Surrounding cells with a syn-
thetic permselective membrane of appropriate molecular weight
cutoff allows the inward diffusion of nutrients and the outward
diffusion of neurotrophic factors; it also blunts that of immuno-
competent molecules and excludes interaction with immunocom-
petent cells, therefore isolating the transplanted cells from the
host immune system (Aebischer et al., 1991). In the case of
capsule failure, the transplanted cells are rejected by the host
immune system (Aebischer et al., 1991). This technique also
allows the continuous delivery of neurotrophic factors within the
nervous system while avoiding the potential problems associated
with repeated invasive procedures. It recently has been applied in
humans for the intrathecal delivery of recombinant human ciliary
neurotrophic factor (CNTF) in amyotrophic lateral sclerosis pa-
tients (Aebischer et al., 1996). The present report shows that the
continuous daily delivery of nanogram levels of GDNF by
polymer-encapsulated engineered cells before medial forebrain
bundle (MFB) axotomy can prevent in rats the degeneration of
SN dopaminergic neurons. It also suggests the existence of an
alternative mechanism for the control of pharmacologically in-
duced rotational behavior in a lesioned nigrostriatal system.
MATERIALS AND METHODS
Animals
Adult female Wistar rats weighing 180–200 gm were obtained from
IFFA-CREDO (L’Arbresle, France) and housed in a standard 12 hr
on/off light cycle with ad libitum access to food and water.
Cells and cell encapsulation
Baby hamster kidney (BHK) cells were transfected with a dihydrofolate
reductase-based expression vector (pNUT, Baetge et al., 1986) containing
the cDNA for rat GDNF (BHK-GDNF) via a calcium phosphate precip-
itation method (Zurn et al., 1994). The cDNA was synthesized by a
reverse transcriptase PCR. The transfected cells were selected by increas-
ing concentrations of methotrexate (Sigma, St. Louis, MO) over a period
of 8 weeks. Nontransfected parent BHK cells were used as controls. All
cells were cultured in DMEM containing 10% fetal calf serum (FCS), 1%
penicillin/streptomycin, and 12 mM L-glutamine (all from Life Technol-
ogies, Paisley, Scotland). The cells were harvested with a standard disso-
ciation medium (Sigma) and suspended in a 50/50 solution of culture
medium and 3% collagen (Zyplast, Collagen, Palo Alto, CA) at a density
of 5 3 105 cells/ml. Then the cell solution was injected into 500 mm inner
diameter poly(ether-sulfone) (PES) fibers (AKZO-Fiber Nobel AG,
Wupperthal, Germany). The fibers were heat-sealed and cut at 5 mm
intervals. The heat-sealed ends of the fibers were reinforced with a
photopolymerized acrylic-based glue and kept in culture medium at 378C
and 5% carbon dioxide for 4 d before transplantation.
Enzyme-linked immunosorbent assay
The basal release of GDNF from polymer-encapsulated BHK-GDNF
cells was determined by ELISA (Promega, Madison, WI). Two days after
encapsulation, the amount of GDNF secreted by the capsules was mea-
sured by placing each capsule into 500 ml of culture medium for 60 min.
The supernatant was removed and analyzed by ELISA. The detection
limit of the assay was 20 pg/ml.
Behavioral analysis
Rats were placed into cylinders attached to rotometers (Rotoscan
Rotometer v5.06, Omnitech, Columbus, OH). They were allowed to rest
for 15 min to adapt to the testing environment and then were injected
intraperitoneally (i.p.) with 5 mg/kg amphetamine sulfate (Research
Biochemicals Incorporated, Natick, MA) dissolved in PBS. Measurement
of rotational activity began 15 min after injection. The animals were
tested for 90 min under minimal external stimuli. The lights were turned
off, and the room was sealed from noise. The rotometer recorded the
number of full clockwise and counterclockwise turns the animals made
during the testing period. This test was performed 1 week before capsule
implantation and 1 week after MFB axotomy. The change in rotation was
calculated as the total number of turns the animal made under amphet-
amine stimulation 1 week after MFB axotomy minus the total number of
turns the animal made 1 week before implantation under similar amphet-
amine stimulation. Clockwise turns (ipsilateral to the lesion) were
counted as positive turns, whereas counterclockwise turns (contralateral
to the lesion) were counted as negative turns. The net number of turns
made during the entire 90 min testing period was counted and divided by
90 to calculate the change in the number of turns per minute.
Figure 1. Diagram depicting the capsule implantation site in relation to
the striatum, the substantia nigra, and the medial forebrain bundle. A,
Sagittal view; B, horizontal view. The implanted capsule is represented by
the hatched area. CPu, Caudate putamen; GP, globus pallidus; EP, en-
teropeduncular nucleus; MFB, medial forebrain bundle; SNc, substantia
nigra pars compacta; SNr, substantia nigra pars reticulata; STN, subtha-
lamic nucleus [adapted from Paxinos and Watson (1986)].
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Capsule implantation
Four days after encapsulation, the animals were implanted with capsules
containing either BHK-GDNF cells (GDNF, n 5 13) or BHK control
cells (BHK, n 5 8). The animals were anesthetized with sodium pento-
barbital (50 mg/kg, i.p.) and placed into a stereotaxic frame (David Kopf
Instruments, Tujunga, CA) with the mouthbar set at23.3 mm (flat skull).
A midline incision was made on the skin covering the skull, and bregma
was determined. A dental drill was used to make a hole through the skull
at a location 3.8 mm caudal to bregma and 3.5 mm lateral to the midline.
A cannula containing the capsule, and attached to a specially designed
inserter, was slowly lowered into the brain to a depth of 8.0 mm below
dura over a period of 5 min. The location of capsule implantation was
lateral to the MFB and rostral to the SN (Fig. 1). Then the outer cannula
was raised slowly while an inner obdurader remained in place to stabilize
the capsule in the brain parenchyma. The skin was closed with 6–0 Vicryl
(Ethicon GmbH KG, Norderstedt, Germany) in a running suture.
Medial forebrain bundle axotomy
One week after capsule implantation, a unilateral MFB axotomy was
performed. The animals were reanesthetized with 50 mg/kg intraperito-
neally of sodium pentobarbital and placed into a stereotaxic frame with
the mouthbar set at 23.3 mm. A hole was drilled at the following
coordinates: 3.8 mm caudal to bregma and 2.4 mm lateral to midline. An
extruding Scouten wire knife (David Kopf Instruments) was lowered 8
mm below the dura. The wire blade was exposed 2 mm in the coronal
plane with the tip facing medially. The knife assembly was raised slowly
2.5 mm and then lowered back to its original position (Knu¨sel et al.,
1992). The wire blade was retracted, and the knife assembly was removed
from the brain. The skin was closed with a 6–0 Vicryl running suture.
Both surgical procedures were performed on the right side of the animals.
Animals subjected to just the MFB axotomy and no capsule implantation
were used as secondary controls (NONE, n 5 10).
Striatal dopamine analysis
After a 1 week survival period, the animals were tested again for
amphetamine-induced rotational asymmetry. The next day, they were
given an overdose of chloral hydrate and killed by transcardial perfusion
of ice-cold PBS with 0.2% ascorbic acid and 5000 U of heparin (Lique-
min, Roche Pharma AG, Reinach, Switzerland). After PBS perfusion, the
brains were extracted quickly, and the striatum was excised, wrapped in
aluminum foil, and rapidly frozen on dry ice (GDNF, n 5 11; BHK, n 5
6; NONE, n 5 8). The capsule was removed from the brain for GDNF
determination, in vitro bioactivity, and histological analysis. The mesen-
cephalon was placed in 4% paraformaldehyde for later immunohisto-
chemical processing. The striatum was placed into a 1.5 ml microcentri-
fuge tube (Eppendorf-Netheler-Hinz-GmbH, Hamburg, Germany)
containing 400 ml of ice-cold 0.1N perchloric acid and dissociated with a
Microson Ultrasonic Cell Disruptor (Heat Systems, Farmingdale, NY).
The mixture was centrifuged at 11,500 rpm for 10 min at 48C. The
supernatant was removed, placed into a filtering centrifuge tube with a
10,000 nominal molecular weight cutoff (Ultrafree-MC, Millipore, Bed-
ford, MA), and centrifuged again. The resulting filtrate was diluted 103
with 0.1N perchloric acid and analyzed on a reverse-phase C18 column
connected to an electrochemical HPLC detector (Millipore). The mobile
phase used (ClinRep, Merck AG, Basel, Switzerland) was acidified with
concentrated phosphoric acid to a pH of 4.08 to ensure a clean separation
of all catecholaminergic products. The protein content of the filtrate also
was analyzed by a bicinchoninic acid (BCA) protein assay (Pierce, Rock-
ford, IL). These values were used to normalize the amount of dopamine
present in each striatal extract. The striatal dopamine content was calcu-
lated as the amount of dopamine present in the striatal extract, as
determined by HPLC analysis, normalized to the amount of protein
present in the extract, as determined by BCA protein analysis. All animals
that had a lesioned versus nonlesioned side dopamine (DA) ratio .50%
were considered to be lesioned insufficiently and were excluded from the
study.
Choline acetyltransferase bioactivity
Capsules were removed from the brains of animals and placed into cell
culture medium overnight until the bioactivity of the capsule was deter-
mined. The bioactivity of GDNF being released from the capsules was
assessed according to the method described by Zurn et al. (1994). Briefly,
embryonic rat (E14) spinal motoneuron cultures were prepared and
exposed, for 6 d, to medium containing no trophic factor, 20 ng/ml of
recombinant rat GDNF (rGDNF, PeproTech, Rocky Hill, NJ), 1 BHK
control capsule, or 1 BHK-GDNF capsule. Choline acetyltransferase
(ChAT) activity was determined by measuring the synthesis, in counts per
minute (cpm), of [3H] acetylcholine from [3H] acetylcoenzyme A over a
20 min period. All values were normalized to the cpm of the control
cultures that received no trophic factor.
Capsule analysis
Capsules were placed in a fixative consisting of 90% sublimated formol
and 10% acetic acid for 3 hr and then into 70% ethanol before glycol
methacrylate (GMA) (Historesin, Leica, Nussloch/Heidelberg, Germany)
processing. Then they were cut at 5-mm-thick sections on a Supercut 2065
(Leica), mounted on glass slides, and stained with 0.5% cresyl violet.
Substantia nigra and striatum morphological analysis
The brains were allowed to post-fix in 4% paraformaldehyde for 24–48 hr
and were transferred into 25% sucrose for 48 hr. The brains were frozen
Figure 2. Histogram showing the average change in turns/min experi-
enced by the animals from 1 week before capsule implantation to 1 week
after MFB axotomy induced by amphetamine stimulation (5 mg/kg, i.p.).
Positive values denote turns ipsilateral to the lesion. GDNF, Animals that
received an implant containing BHK-GDNF cells (n 5 13); BHK, animals
that received an implant containing BHK control cells (n 5 8); NONE,
animals that received no implant (n5 10). *p, 0.05 (vs BHK), #p, 0.02
(vs NONE), ANOVA. Values are mean 6 SEM.
Figure 3. Histogram showing the percentage of striatal dopamine content
of the right (lesioned) side versus the left (nonlesioned) side, as deter-
mined by HPLC analysis. Each striatal content was normalized to the
amount of protein present in the sample.GDNF, Animals that received an
implant containing BHK-GDNF cells (n 5 11); BHK, animals that re-
ceived an implant containing BHK control cells (n 5 6); NONE, animals
that received no implant (n 5 8). Values are mean 6 SEM.
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in dry ice powder, and coronal sections were cut on a sliding microtome
cryostat (Cryocut 1800, Leica) at a temperature of 2248C and a thickness
of 25 mm. All slices throughout the SN were collected and stored in 48
well trays (Costar, Cambridge, MA) as free-floating sections in PBS
containing 0.12 mM sodium azide. The trays were stored at 48C until
immunohistochemical processing. In six brains (2 from each group) that
were not subjected to striatal dopamine analysis, the striatum was cut and
every fourth section was collected in a manner similar to that of the SN.
Tyrosine hydroxylase staining
Substantia nigra. The sections first were quenched in a 0.1% solution of
phenylhydrazine (Merck AG) at 378C for 1 hr to reduce endogenous
peroxidase activity. Then they were incubated in a blocking solution
consisting of 7% normal goat serum (NGS, Dako Diagnostics AG, Zug,
Switzerland) and 0.5% Triton X-100 (Sigma). The sections were agitated
at a speed of 100 rpm for 2 hr at ambient room temperature. They were
incubated in a solution containing 5% monoclonal TH antibody (Boehr-
inger Mannheim GmbH, Mannheim, Germany) and 5% NGS. The sec-
tions were left overnight at 48C. After thorough rinsing with PBS, the
sections were incubated in a 3% NGS solution containing 1% goat-a-
mouse (GaM) peroxidase-antiperoxidase (PAP)-conjugated immuno-
globulins (Dako Diagnostics AG) for 3 hr at room temperature. Then the
sections were visualized with a 0.5% 3,39-diaminobenzidine (DAB,
Sigma) and 0.01% hydrogen peroxide solution for;30 sec, mounted onto
glass slides, and counterstained with 0.5% cresyl violet.
Striatum. The protocol was modified slightly for striatal sections. After
identical phenylhydrazine quenching, the sections were agitated over-
night at 100 rpm at ambient room temperature in a blocking solution
consisting of 10% NGS and 0.1% Triton X-100. This procedure was
followed by a two-night incubation at 48C in a primary antibody solution
containing 2% monoclonal TH antibody, 5% NGS, and 0.1% Triton
X-100. After thorough rinsing with PBS, the sections were agitated at 100
rpm and 48C in a secondary antibody solution of 0.5% GaM antibody
(Vector Laboratories, Burlingame, CA), 1% NGS, 0.1% Triton X-100,
and 1% normal rat serum (NRS) (Dako Diagnostics AG) for 3 hr. The
sections were, once again, rinsed with PBS and then subjected to an
avidin–biotin complex reaction (Vectastain Elite ABC kit, Vector Lab-
oratories) for 3 hr at 48C and 100 rpm. Then, after a final series of washes,
Figure 4. Micrographs showing TH-IR staining in the striatum 1 week after MFB axotomy in animals that received capsules containing either
BHK-GDNF cells (A, B) or BHK control cells (C, D). A and C show the control (nonlesioned) side, whereas B and D show the lesioned side. Note the
lack of TH-IR staining on the lesioned side in both cases, illustrating the absence of regrowth or sprouting of remaining fibers into the deinnervated
striatum in either case. Scale bar, 200 mm.
Figure 5. Histogram showing the percentage of TH-positive SN pars
compacta neurons on the right (lesioned) side versus left (nonlesioned)
side. Counts are based on at least 12 sections throughout the whole SN.
Total number of calculations is described in Materials and Methods.
*p , 0.0015 (vs NONE); #p , 0.0003 (vs BHK), ANOVA. Values are
mean 6 SEM.
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the sections were visualized by diaminobenzidine (DAB) in a manner
similar to that of the SN sections.
Morphological quantification analysis
The number of TH-IR SN pars compacta neurons was determined by
counting each stained section at a magnification of 1003. At least 12
sections per brain, distributed along the rostal–caudal length of the SN
pars compacta, were counted. All TH-IR bodies in the A9 SN region were
counted as described by Bjo¨rklund and Lindvall (1984). After counting,
the total number of TH-IR neurons was calculated by taking the average
cell number between two counted sections and multiplying it by the
number of uncounted intervening sections. So that the accuracy of this
estimation method could be tested, one test brain had 48 consecutive
sections stained for TH-IR. The total number was compared with a
calculated number based on eight sections taken at six section intervals.
The calculated number was found to be within 5% of the actual number
(data not shown). This method is a specific case of the method described
previously by Abercrombie (1946), in that the average neuronal diameter
is very similar to the thickness of the section. The total number of TH-IR
SN pars compacta neurons on the lesioned (right) side was divided by the
total number of TH-IR SN pars compacta neurons on the nonlesioned
(left) side to obtain a survival percentage.
Statistical analysis
The data obtained were analyzed for significance with ANOVA, fol-
lowed by a Fisher’s PLSD post hoc test (StatView 4.0, Abacus Con-
cepts, Berkeley, CA).
Figure 6. Micrographs showing TH-IR staining in the SN pars compacta 1 week after MFB axotomy. Low power pictures of coronal sections show the
SN pars compacta. A, A typical control animal with no implant. B, A typical control animal that had received a capsule containing control BHK cells. C,
D, Two typical animals that had received a capsule containing GDNF-secreting BHK cells. Note the almost total loss of TH-positive staining in the two
control groups (A, B), whereas the group that received BHK-GDNF cells showed substantial rescue (C, D). Scale bar, 500 mm. High power photographs
show TH-IR staining in the nonlesioned (E) and lesioned (F ) SN pars compacta of the animal shown in D that had received a BHK-GDNF implant. Note
the intense TH-IR staining and extensive dendritic sprouting in the lesioned SN pars compacta (F ), as compared with the nonlesioned SN pars compacta
(E). Scale bar, 100 mm.
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RESULTS
Behavioral analysis
The capsules were well tolerated by all the animals; no spontane-
ous behavioral deficits were observed in any of the three groups.
GDNF, however, significantly reduced the amphetamine-induced
number of turns experienced by animals 1 week after MFB axo-
tomy (1.26 1.0 turns/min), as compared with control animals that
received either implants containing BHK cells (6.2 6 2.3 turns/
min; p, 0.03) or no implants (6.96 1.7 turns/min; p, 0.02) (Fig.
2). GDNF decreased the change in the number of turns per
minute to ;18% of the change in the number of turns per minute
of the control groups.
In 5 of the 13 animals that received BHK-GDNF implants,
turning contralateral to the lesion while under the influence of
amphetamine was exhibited 1 week after MFB axotomy. This
behavior was not observed in any of the animals receiving control
(BHK or NONE) implants.
Biochemical and immunohistochemical analysis of
the striatum
The adequacy of the MFB lesion was ascertained by a decrease of
striatal dopamine content. Animals that received an implant
of BHK-GDNF had an average normalized striatal DA content of
19.1 6 4.7% (GDNF, n 5 11) of the lesioned side, as compared
with the nonlesioned side. The lesioned versus nonlesioned DA
striatal ratio was 32.2 6 8.7% in animals that received parent
BHK-containing capsules (BHK, n 5 6) and 9.3 6 4.7% in the
animals lesioned only (NONE, n 5 8; Fig. 3).
Immunohistochemical analysis was performed on the striata of
animals who were not subjected to striatal dopamine analysis
(GDNF, Fig. 4A,B; BHK, Fig. 4C,D). The striata were stained for
TH-IR. The nonlesioned striata showed dark, robust TH-IR stain-
ing (Fig. 4A,C), whereas the striata ipsilateral to the MFB axo-
tomy revealed no TH-IR staining (Fig. 4B,D), showing the ab-
sence of sprouting or regeneration into the lesioned striatum.
Immunohistochemical analysis of the substantia nigra
A significant sparing of the TH-IR of the SN neurons was ob-
served in the animals implanted with GDNF-releasing capsules, as
compared with animals implanted with encapsulated BHK cells or
animals that were lesioned only. BHK-GDNF-implanted animals
had 64.9 6 7.2% TH-positive cells on the lesioned side, as com-
pared with the nonlesioned side, whereas control animals had
27.2 6 3.5% (BHK; p , 0.0005) and 29.1 6 4.6% (NONE; p ,
0.0015) TH-positive cells (Figs. 5, 6). Similar results were obtained
when the ventral tegmental area (VTA or A10) TH-positive cells
also were counted and included in the calculations (data not
shown). In animals that received an implant containing BHK-
GDNF cells, the dendritic network surrounding the cells was
mostly preserved. However, in animals that received either con-
trol or no implants, the surrounding dendritic network was prac-
tically nonexistent. In one animal that received a BHK-GDNF
implant (Table 1; Fig. 6D–F), the number of TH-IR neurons on
the lesioned side was actually greater than the number on the
control side. In this animal, an important dendritic sprouting of
TH-positive fibers was observed within the nigra. However, no
statistically significant correlation could be made between the
number of nigral TH-IR neurons remaining and the extent of
turning in animals that exhibited contralateral amphetamine-
induced turning after axotomy. The same was true when compar-
ing striatal DA content and the extent of turning (data not
shown).
Bioactivity and morphological appearance of the
retrieved implants
At the time of implant, capsules containing BHK-GDNF cells
were determined to be releasing ;5 ng of GDNF/capsule per day
(data not shown). On explantation, the capsules containing BHK-
GDNF cells continued to release bioactive GDNF, as measured
by ChAT activity in spinal motoneuron cultures. GDNF continu-
ously released from encapsulated BHK-GDNF cells significantly
increased the ChAT activity by 4536 58% ( p, 0.0001 vs control;
p , 0.0002 vs BHK), whereas 20 ng/ml of powdered recombinant
rat GDNF, used as a positive control, increased the spinal mo-
toneuron culture ChAT activity by 238 6 26% ( p , 0.05 vs
Figure 7. A, Histogram showing the effect of explanted encapsulated cells
on the activity of ChAT on spinal motoneuron cultures. Control wells
(negative control) received no trophic factor (100%). Two wells per series
received 20 ng/ml rat recombinant GDNF (positive control). All counts
were normalized by the number of counts in the negative control. The
capsules containing BHK-GDNF cells significantly increased the ChAT
activity of the cultures. *p , 0.03 (vs control); **p , 0.0001 (vs control);
#p , 0.0002 (vs BHK), ANOVA. Values are mean 6 SEM. B, Micro-
graph showing encapsulated BHK-GDNF cells on explantation at 2 weeks.
Note the good viability of the transplanted cells. Mem, Membrane. Scale
bar, 100 mm.
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control) (Fig. 7A). Capsules containing BHK control cells in-
creased ChAT activity by 139 6 12%. Wells receiving no trophic
factors were used as controls (100 6 2%).
After in vitro testing, the capsules were processed for morpho-
logical analysis. Figure 7B shows a photomicrograph of a capsule
retrieved at 2 weeks after implantation. All capsules contained
living cells surrounding small necrotic cores.
DISCUSSION
MFB axotomy leads to the degeneration of dopaminergic neurons
of the SN. The ability to prevent the degeneration of these
neurons and maintain their phenotype holds promise for the
treatment of PD. This report illustrates that continuous delivery
of low levels of GDNF by polymer-encapsulated GDNF-secreting
cells can prevent the degeneration and preserve the phenotype of
the dopaminergic cell bodies that normally degenerate after a
MFB axotomy. In lesioned animals that received control implants
or no implants, the number of TH-IR neurons was decreased
drastically throughout the entire SN pars compacta and VTA. The
morphology of the cells rescued by GDNF was indistinguishable
from the control nonlesioned side. The dendritic network sur-
rounding the rescued cells was mostly preserved. Although GDNF
rescued cell bodies and dendrites, it did not induce axonal regen-
eration into the striatum within the 2 week observation period.
This is confirmed by the low levels of DA detected in the striatum
after axotomy (Fig. 3) and by the absence of TH-IR staining in the
striatum (Fig. 4). Longer term experiments are, however, needed
to assess the capability of GDNF to induce regrowth of dopami-
nergic fibers within the lesioned striatum.
The ability of other neurotrophic factors, such as ciliary neuro-
trophic factor (CNTF) and brain-derived neurotrophic factor
(BDNF), to prevent neuronal degeneration in this same axotomy
model was tested previously. CNTF, delivered from a pump for
14 d (1.5 mg/d) after lesioning, was shown to protect the axoto-
mized neurons from degeneration but did not prevent the de-
crease in their TH-IR (Hagg and Varon, 1993), whereas BDNF
had no rescue effect on these cells, despite numerous injection
protocols [intracerebral ventricular injections, 0.58 mg/2 d for
18 d; MFB or SN injections, 0.224 mg/d for 18 d (Knu¨sel et al.,
1992); or SN injections, 1 mg/2 d for 18 d (Lapchak et al., 1993)]
beginning at the time of the lesion. In contrast, the current
experiments show that pretreating with continually released low
levels of GDNF can prevent both the degeneration and the loss of
TH-IR in the axotomized dopaminergic neurons.
In the present experiments, 73% of the SN neurons degenerate
by 1 week postlesion (Fig. 2), whereas a slower degeneration has
been reported by other groups using similar techniques (Knu¨sel et
al., 1992; Hagg and Varon, 1993; Lapchak et al., 1993; Beck et al.,
1995). This discrepancy could be attributable to the fact that the
exact location of our axotomy is more caudal and thus closer to
the cell bodies than most of the other axotomies reported (Hagg
and Varon, 1993; Lapchak et al., 1993; Beck et al., 1995). The
27% survival we see after 1 week is, however, similar to the 23%
endpoint survival reported by Brecknell et al. (1995) at 10 weeks.
This implies that although the time point we have chosen is much
shorter than that reported by other groups, it is still morpholog-
ically near the final endpoint of the degenerative process.
The amount of GDNF released in the current study is at least
three orders of magnitude lower than the amount of GDNF that
has been injected by other groups. Their values range from 10 mg
(Hudson et al., 1995) to 100 mg (Hoffer et al., 1994; Bowenkamp
et al., 1995) (single bolus injections). Other groups have used
multiple injections that total from 20 mg (Beck et al., 1995) to 70
mg (Sauer et al., 1995) at 2 weeks. Such repeated injections of
GDNF have been shown to prevent the degeneration of dopami-
nergic neurons after MFB axotomy (Beck et al., 1995) and striatal
6-OHDA injections (Sauer et al., 1995). However, the large
amounts used in these studies raise the possibility of unwanted
side effects. Because it has been shown that GDNF also affects
nondopaminergic systems, and given the wide expression of
GDNF mRNA within both the embryonic (Schaar et al., 1993;
Stro¨mberg et al., 1993; Humpel et al., 1994; Springer et al., 1994)
and adult nervous system (Pochon and Aebischer, unpublished
observations), the large amounts injected also may induce changes
to nondopaminergic systems.
Although the amount delivered in the present study is much
lower than that administered by other groups, significant rescue of
the axotomized neurons and, in some cases, increased TH-IR
expression in the axotomized neurons still was observed. In one
animal, the intensity of staining and the number of TH-IR cells on
the lesioned side was even greater than that on the nonlesioned
side (Table 1; Fig. 6D–F). This apparent increase is, in all likeli-
hood, attributable to an upregulation of TH expression in
dopaminergic neurons. This animal also exhibited intense
amphetamine-induced turning contralateral to the lesion, as if the
striatum on the lesioned side were intact and the striatum on the
opposite side were lesioned. Our HPLC results have shown that
this was not the case. This overcorrection of the amphetamine-
induced rotation after BHK-GDNF capsule implantation was
observed in 5 of 13 animals. This behavior was not observed in any
animals receiving control (BHK or NONE) implants. On average,
the number of turns/minute in animals that had received GDNF
implants was significantly lower than that exhibited by the animals
in the control groups (Fig. 5). Similar corrections were observed
by Hoffer et al. (1994) and Bowenkamp et al. (1995) in 6-OHDA-
lesioned animals under the influence of apomorphine. Recently,
Gash et al. (1996) have reported behavioral improvement in
Table 1. Data values for the animal shown in figure 6D–F
Control side Lesion side % (L/C)
Striatal dopamine content (pmol/mg) 5.77 1.07 18.54
Control side Lesion side % (L/C)
Number of TH-IR neurons 5818 7490 128.74
Before capsule implantation After MFG axotomy D Turns/min
Amphetamine-induced rotations (turns/min) 20.33 26.21 25.88
Values for striatal DA content, number of TH1 neurons, and number of turns /min for the animal shown in Figure 6D–F. Note the apparent increase in the number of TH-IR
on the lesioned side, as compared with the nonlesioned side. Also note the strong contralateral (negative) turning experienced by the animal after axotomy. Turning
contralateral to the lesion was also seen in four additional animals that had received a capsule containing GDNF-secreting BHK cells.
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MPTP-treated rhesus monkeys injected with multiple bolus (100
mg) injections of GDNF in the absence of recovery of dopamine
in the striatum. These results seem to imply that the striatum is
not absolutely necessary for the amelioration of drug-induced
rotational asymmetry. The effects of GDNF on other basal ganglia
functions such as sensory neglect, paw reaching, disengaging be-
havior, and aphagia and adipsia (Brundin and Lindvall, 1993)
need to be examined.
A possible mechanism may lie in the dendro-dendritic network
interconnecting the SN pars compacta neurons and/or the com-
pacta neurons with the SN pars reticulata neurons. Ruffieux and
Schultz (1980) have shown that these connections are sensitive to
DA. They found that the neurons of the SN pars reticulata are
activated, whereas those of the pars compacta are depressed, on
the application of DA. The nigral application of GDNF, with its
protective and sprouting effects on the dopaminergic SN neurons,
may induce a modification of these dendro-dendritic control
loops. In animals that have undergone MFB axotomy, DA stores
in the preserved SN pars compacta are released at the dendritic
sites, as opposed to the axonal sites in the striatum, on the
application of amphetamine. This increase in DA release within
the nigra may cause significant alterations in the output of the SN
pars reticulata neurons (Fig. 8). This hypothesis is supported by
the findings that the unilateral application of dopamine (Jackson
and Kelly, 1983) or apomorphine (Kozlowski et al., 1980; LaHoste
and Marshall, 1990) directly into the substantia nigra induces
strong contralateral rotation in animals that had been rendered
supersensitive by unilateral 6-OHDA lesioning. This indicates
that supersensitivity is occurring in the SN pars compacta and not
the SN pars reticulata, because supersensitivity of the SN pars
reticulata receptors would activate those neurons and, conse-
quently, further inhibit output from the thalamus. On the con-
trary, the development of supersensitivity in the SN pars compacta
should result in the hyperactivity of the ipsilateral thalamic nuclei
(i.e., strong contralateral rotations). So that this hypothesis can be
examined further, direct nigral application of D1 and D2 receptor
agonists into normal, lesioned, and GDNF-treated normal and
lesioned SN pars compacta and SN pars reticulata is required.
Recording the firing rate of pars reticulata nigral neurons in
animals exhibiting overcorrection under amphetamine stimula-
tion also should provide better insight into the functional activity
of the nigral system.
In summary, the present study suggests a possible fast basal
ganglia plasticity in response to certain pharmacological stimuli.
This plasticity may point toward the actual mechanisms involved
in the control of pharmacologically induced rotational behavior.
Furthermore, this work also illustrates that continuous low level
delivery of GDNF has potent dopaminergic effects in vivo, an
Figure 8. Diagram depicting hypothesized basal ganglia circuitry in (A) normal basal ganglia. B, Parkinsonian basal ganglia with GDNF. GPe, Globus
pallidus externus; STN, subthalamic nucleus; GPi, globus pallidus internus (enteropeduncular nucleus); SNc, substantia nigra pars compacta; SNr,
substantia nigra pars reticulata; VA-VL, ventroanterior and ventrolateral nuclei of the thalamus; D1, D2, D1 and D2 receptors of the striatum.
332 J. Neurosci., January 1, 1997, 17(1):325–333 Tseng et al. • GDNF Reduces Drug-Induced Rotation by a Nonstriatal Mechanism
observation holding promise for the treatment of Parkinson’s
disease.
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